Table 2 HLA-G and -F isoform distribution in the molecular subtypes.

From: HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment

Biomarker

HER2+ (n = 28)

Luminal B-like (n = 49)

Triple-negative (n = 38)

P value

HLA-F1

0.26 (0.09, 0.46)

0.27 (0.19, 0.44)

0.27 (0.15, 0.5)

0.82

HLA-F3

0.58 (0.10, 2.23)

0.57 (0.15, 2.66)

0.92 (0.26, 2.11)

0.76

HLA-G1

2.92 (1.33, 5.97)

2.85 (1.93, 4.54)

2.69 (1.5, 8.86)

0.80

HLA-G2

0.00 (0.00, 0.00)

0.00 (0.00, 0.00)

0.00 (0.00, 0.00)

0.92

HLA-G3

1.48 (0.74, 3.87)

2.16 (0.74, 3.96)

2.57 (1.37, 4.99)

0.17

HLA-G5

1.87 (0.79, 3.22)

1.37 (0.50, 3.18)

1.17 (0.35, 5.95)

0.72

HLA-G6

0.18 (0.10, 0.45)

0.19 (0.11, 0.47)

0.19 (0.05, 0.37)

0.73

  1. Protein bands from Western blots were quantified using ImageJ. GAPDH was used as an internal protein control, and placental tissue was used as a reference sample for each blot. The isoform expression pattern was determined semiquantitatively by normalizing to GAPDH relative to the reference sample (HLA isoform/GAPDH ratio). The median and interquartile range (25th percentile, 75th percentile) of the HLA isoform/GAPDH ratio were calculated for each molecular subtype, and P values were calculated using the Kruskal–Wallis test.
  2. HER2 human epidermal growth factor receptor 2, HLA human leukocyte antigen.
Back to article page